Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma.

Neuhaus T, Luyken J.

Target Oncol. 2012 Dec;7(4):247-51. doi: 10.1007/s11523-012-0235-8. Epub 2012 Oct 23.

PMID:
23090205
2.

Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.

Pagano M, Sierra NM, Panebianco M, Rossi G, Gnoni R, Bisagni G, Boni C.

Anticancer Res. 2014 Sep;34(9):5105-10.

PMID:
25202099
3.

Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma.

Bisagni G, Rossi G, Cavazza A, Sartori G, Gardini G, Boni C.

J Thorac Oncol. 2009 Jun;4(6):773-5. doi: 10.1097/JTO.0b013e3181a52e25.

4.

Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.

Zavaglia C, Airoldi A, Mancuso A, Vangeli M, ViganĂ² R, Cordone G, Gentiluomo M, Belli LS.

Eur J Gastroenterol Hepatol. 2013 Feb;25(2):180-6. doi: 10.1097/MEG.0b013e328359e550. Review.

PMID:
23044808
5.

[Three Patients with Acute Myocardial Infarction Associated with Targeted Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case Report].

Takagi K, Takai M, Kawata K, Horie K, Kikuchi M, Kato T, Mizutani K, Seike K, Tsuchiya T, Yasuda M, Yokoi S, Nakano M, Ushikoshi H, Miyazaki T, Deguchi T.

Hinyokika Kiyo. 2015 Sep;61(9):347-51. Japanese.

6.

Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.

Simonelli M, Zucali PA, Suter MB, Lorenzi E, Rubino L, Fatuzzo G, Alloisio M, Santoro A.

Future Oncol. 2015;11(8):1223-32. doi: 10.2217/fon.14.318. Review.

PMID:
25832879
7.

Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma.

Garuti F, Camelli V, Spinardi L, Bucci L, Trevisani F.

Tumori. 2016 Nov 11;102(Suppl. 2). doi: 10.5301/tj.5000504.

PMID:
27079903
8.

Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience.

Vincenzi B, Silletta M, Schiavon G, Frezza AM, Del Vescovo R, Zobel BB, Santini D, Dei Tos AP, Tonini G.

Expert Opin Investig Drugs. 2013 Jan;22(1):1-7. doi: 10.1517/13543784.2013.742886. Epub 2012 Nov 16.

PMID:
23157681
9.

Case of sorafenib-induced thyroid storm.

Haraldsdottir S, Li Q, Villalona-Calero MA, Olencki TE, Kendra K, Ing SW.

J Clin Oncol. 2013 Jun 1;31(16):e262-4. doi: 10.1200/JCO.2012.46.7142. Epub 2013 Apr 22. No abstract available.

PMID:
23610115
10.

Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report.

Li XF, Chen Q, Huang WX, Ye YB.

Med Oncol. 2009;26(2):157-60. doi: 10.1007/s12032-008-9100-0. Epub 2008 Oct 10.

PMID:
18846437
11.

Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma.

Buti S, Donini M, Sergio P, Garagnani L, Schirosi L, Passalacqua R, Rossi G.

J Clin Oncol. 2011 Nov 20;29(33):e803-5. doi: 10.1200/JCO.2011.36.6427. Epub 2011 Oct 3. No abstract available.

PMID:
21969494
12.

Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.

Sajithlal GB, Hamed HA, Cruickshanks N, Booth L, Tavallai S, Syed J, Grant S, Poklepovic A, Dent P.

Mol Pharmacol. 2013 Oct;84(4):562-71. doi: 10.1124/mol.113.088005. Epub 2013 Jul 22.

13.

Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).

Chevreau C, Le Cesne A, Ray-Coquard I, Italiano A, Cioffi A, Isambert N, Robin YM, Fournier C, Clisant S, Chaigneau L, Bay JO, Bompas E, Gauthier E, Blay JY, Penel N.

Cancer. 2013 Jul 15;119(14):2639-44. doi: 10.1002/cncr.28109. Epub 2013 Apr 15.

14.

[Chemotherapy for thymic carcinoma].

Okuma Y.

Gan To Kagaku Ryoho. 2012 May;39(5):702-7. Japanese.

PMID:
22584319
15.

Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.

Ströbel P, Bargou R, Wolff A, Spitzer D, Manegold C, Dimitrakopoulou-Strauss A, Strauss L, Sauer C, Mayer F, Hohenberger P, Marx A.

Br J Cancer. 2010 Jul 13;103(2):196-200. doi: 10.1038/sj.bjc.6605740. Epub 2010 Jun 22.

16.

Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.

Funakoshi T, Latif A, Galsky MD.

J Hum Hypertens. 2013 Oct;27(10):601-11. doi: 10.1038/jhh.2013.30. Epub 2013 May 2. Review.

PMID:
23636006
17.

Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer.

Bellesoeur A, Carton E, Mir O, Groussin L, Blanchet B, Billemont B, Clerc J, Goldwasser F.

Invest New Drugs. 2014 Jun;32(3):569-72. doi: 10.1007/s10637-013-0052-7. Epub 2014 Jan 8.

PMID:
24399106
18.

Chemotherapy and targeted agents for thymic malignancies.

Girard N.

Expert Rev Anticancer Ther. 2012 May;12(5):685-95. doi: 10.1586/era.12.29. Review.

PMID:
22594902
19.

Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.

Huillard O, Boissier E, Blanchet B, Thomas-Schoemann A, Cessot A, Boudou-Rouquette P, Durand JP, Coriat R, Giroux J, Alexandre J, Vidal M, Goldwasser F.

Expert Opin Drug Saf. 2014 May;13(5):663-73. doi: 10.1517/14740338.2014.907270. Epub 2014 Apr 3. Review.

PMID:
24693873
20.

Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.

Sotiropoulos GC, Nowak KW, Fouzas I, Vernadakis S, Kykalos S, Klein CG, Paul A.

Transplant Proc. 2012 Nov;44(9):2754-6. doi: 10.1016/j.transproceed.2012.09.022.

PMID:
23146514

Supplemental Content

Support Center